Developer docs
API playgroundTry for free, no card

Search company profiles

Mersana Therapeutics

Full company profile

uuid00034r9

Namestring
Mersana Therapeutics
Legal namestring
Mersana Therapeutics, Inc.
Websiteurl
mersana.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Mersana Therapeutics was a clinical-stage biopharmaceutical company that developed antibody-drug conjugates (ADCs) for the treatment of cancer. Headquartered in Cambridge, Massachusetts and founded in 2001, the company operated a proprietary ADC platform with novel conjugation chemistry and linker technology, targeting two distinct biological pathways: B7-H4 (via Emi-Le / emiltatug ledadotin) and STING agonism (via XMT-2056). Its lead asset, Emi-Le, was a clinical-stage B7-H4-directed ADC in development for adenoid cystic carcinoma (ACC), a rare solid tumor with no FDA-approved therapies. XMT-2056, a STING-agonist ADC for HER2-positive cancers, was licensed to GSK in 2022 in a deal worth up to $1.36 billion in milestones but was later placed on FDA partial clinical hold and returned.

The company generated revenue exclusively through licensing agreements and milestone payments from pharmaceutical partners, as it had no commercialized products. The GSK partnership was the dominant commercial relationship and provided the principal validation of Mersana's platform, but that relationship was terminated by GSK in April 2026. Mersana's customer base was effectively limited to rare cancer patients enrolled in clinical trials, with no traditional distribution or product marketing infrastructure. The company had a headcount in the 101–250 range (firmographics), consistent with a clinical-stage biotech operating multiple IND-stage programs.

In January 2026, Mersana was acquired by Day One Biopharmaceuticals for $25 per share in cash plus contingent value rights worth up to $30.25 per share, with a total deal value of approximately $285 million. The company became a wholly owned subsidiary and was immediately delisted from Nasdaq. Day One was subsequently acquired by Servier in March 2026 to expand Servier's rare oncology portfolio, placing Emi-Le within a larger commercial-stage organization.

Short descriptiontext

Mersana Therapeutics was a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer, including Emi-Le for adenoid cystic carcinoma and XMT-2056 for HER2 cancers. Acquired by Day One Biopharmaceuticals in January 2026.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
antibody-drug conjugates, oncology therapeutics, targeted cancer therapy, biopharmaceutical development, ADC platform
Industry1 code
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
Social media profiles2 records
Revenue model1 record
1Licensing and milestone payments
TypeLicensing Royalties
Description

Mersana generated revenue through licensing agreements with pharmaceutical partners, receiving milestone payments upon achievement of clinical and regulatory milestones. GSK partnership provided $100 million option payment; milestone payments from GSK were mentioned in Q3 2025 results.

openpr.com
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Emi-Le (emiltatug ledadotin)
Description

Antibody drug conjugate targeting B7-H4 for treating adenoid cystic carcinoma

ir.dayonebio.com
Core offering1 text field

Mersana Therapeutics developed clinical-stage antibody-drug conjugates (ADCs) for the treatment of cancer. Its lead candidate, Emi-Le (emiltatug ledadotin), was a B7-H4-directed ADC in development for adenoid cystic carcinoma, a rare cancer with no approved therapies. The company also developed XMT-2056, a STING agonist ADC licensed to GSK. Revenue was generated through licensing and milestone payments from pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 60.57% share tender acceptance in acquisition
Product overview1 text field

Mersana Therapeutics was a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment. The company's primary product was Emi-Le (emiltatug ledadotin), a B7-H4-directed ADC being developed for adenoid cystic carcinoma. Mersana also developed XMT-2056, a STING agonist ADC that was licensed to GSK. The company operated its proprietary ADC platform technology and was acquired by Day One Biopharmaceuticals in January 2026 for approximately $285 million.

Product and service2 records
1Emi-Le (emiltatug ledadotin)
CategoryOncology Biopharmaceuticals
Description

A clinical-stage antibody-drug conjugate (ADC) targeting B7-H4 for the treatment of adenoid cystic carcinoma (ACC), a rare cancer with no approved therapies. Developed by Mersana Therapeutics and now advanced by Day One Biopharmaceuticals following its January 2026 acquisition of Mersana.

2XMT-2056
CategoryOncology Biopharmaceuticals
Description

A STING agonist antibody-drug conjugate (ADC) for HER2-positive cancers, originally licensed to GSK. Development was discontinued in April 2026 after GSK terminated the partnership following an FDA partial clinical hold related to serious bleeding events.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMajor (Terminated)TypeStrategic or Co-development PartnerAnnounced on2026-04-29
Description

GSK partnered with Mersana on XMT-2056, a STING-agonist ADC for HER-2 cancers. GSK terminated the partnership in April 2026, walking away from a $100 million option deal. The drug had been placed on FDA partial clinical hold due to serious bleeding events including five deaths. GSK had originally acquired the program in 2022 in a deal worth up to $1.36 billion in milestones.

Strategic tierCore (Acquisition Completed)TypeStrategic or Co-development PartnerAnnounced on2026-01-06
Description

Day One Biopharmaceuticals acquired Mersana Therapeutics in January 2026 for $25 per share in cash plus contingent value rights worth up to $30.25 per share. The acquisition added Emi-Le (B7-H4-directed ADC) to Day One's pipeline for treating adenoid cystic carcinoma. Mersana became a wholly owned subsidiary with immediate delisting from Nasdaq.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

ADC pioneer whose Elaherte (mirvetuximab) was acquired by AbbVie for $10.1B in 2024. Directly comparable to Mersana as a clinical-to-commercial ADC specialist targeting oncology indications.

TypeBroad incumbent
Description

Leading ADC company with approved products (Adcetris, Padcev, Tukysa) acquired by Pfizer for $43B. Directly comparable ADC platform company with both early-stage assets and commercialized products.

TypeBroad incumbent
Description

Co-developer of Enhertu (with AstraZeneca), a blockbuster HER2 ADC. Comparable as a major ADC innovator and commercializer with deep pipeline in antibody-drug conjugates across multiple targets.

TypeDirect peer
Description

Clinical-stage ADC/ISAC developer with proprietary platform technology. Comparable as a small-cap, clinical-stage ADC company developing next-generation antibody conjugates for oncology indications.

TypeDirect peer
Description

Clinical-stage ADC company developing novel antibody-drug conjugates for solid tumors. Directly comparable as a clinical-stage ADC specialist targeting oncology with proprietary platform technology.

TypeDirect peer
Description

Clinical-stage oncology company developing ADC and immuno-oncology therapeutics. Comparable as a clinical-stage biopharma focused on ADC development for cancer treatment.

TypeBroad incumbent
Description

Acquirer of Mersana and operator of Emi-Le post-2026; commercial-stage rare oncology company with FDA-approved OJEMDA. Comparable as a rare pediatric oncology-focused biopharma now integrating Mersana's ADC asset.

TypeEmerging player
Description

Emerging ADC developer focused on next-generation antibody-drug conjugates with novel payload and linker technologies. Comparable as an emerging European-headquartered ADC platform company in clinical-stage development.

TypeBroad incumbent
Description

Major ADC player through Enhertu (with Daiichi Sankyo) and Datroway. Comparable as a large pharma with significant ADC franchise investments, demonstrating the strategic value of ADC assets Mersana-style companies can attract.

TypeBroad incumbent
Description

Owns Trodelvy, a TROP2-directed ADC acquired through the Immunomedics deal. Comparable as a major biopharma with commercialized ADC assets and ongoing investments in antibody-drug conjugate development.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mersana Therapeutics

Oncology Biopharmaceuticalsmersana.com

Mersana Therapeutics was a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer, including Emi-Le for adenoid cystic carcinoma and XMT-2056 for HER2 cancers. Acquired by Day One Biopharmaceuticals in January 2026.

What Mersana Therapeutics does

Mersana Therapeutics was a clinical-stage biopharmaceutical company that developed antibody-drug conjugates (ADCs) for the treatment of cancer. Headquartered in Cambridge, Massachusetts and founded in 2001, the company operated a proprietary ADC platform with novel conjugation chemistry and linker technology, targeting two distinct biological pathways: B7-H4 (via Emi-Le / emiltatug ledadotin) and STING agonism (via XMT-2056). Its lead asset, Emi-Le, was a clinical-stage B7-H4-directed ADC in development for adenoid cystic carcinoma (ACC), a rare solid tumor with no FDA-approved therapies. XMT-2056, a STING-agonist ADC for HER2-positive cancers, was licensed to GSK in 2022 in a deal worth up to $1.36 billion in milestones but was later placed on FDA partial clinical hold and returned.

The company generated revenue exclusively through licensing agreements and milestone payments from pharmaceutical partners, as it had no commercialized products. The GSK partnership was the dominant commercial relationship and provided the principal validation of Mersana's platform, but that relationship was terminated by GSK in April 2026. Mersana's customer base was effectively limited to rare cancer patients enrolled in clinical trials, with no traditional distribution or product marketing infrastructure. The company had a headcount in the 101–250 range (firmographics), consistent with a clinical-stage biotech operating multiple IND-stage programs.

In January 2026, Mersana was acquired by Day One Biopharmaceuticals for $25 per share in cash plus contingent value rights worth up to $30.25 per share, with a total deal value of approximately $285 million. The company became a wholly owned subsidiary and was immediately delisted from Nasdaq. Day One was subsequently acquired by Servier in March 2026 to expand Servier's rare oncology portfolio, placing Emi-Le within a larger commercial-stage organization.

Mersana Therapeutics firmographics

Firmographics
Name
Mersana Therapeutics
Legal name
Mersana Therapeutics, Inc.
Website
https://mersana.com
Company type
Private
Founded year
2017
Operating status
Acquired
Headcount range
51–100 employees
Short description
Mersana Therapeutics was a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer, including Emi-Le for adenoid cystic carcinoma and XMT-2056 for HER2 cancers. Acquired by Day One Biopharmaceuticals in January 2026.
Ownership category
akta.pro rank

Mersana Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody-drug conjugates
  • Oncology therapeutics
  • Targeted cancer therapy
  • Biopharmaceutical development
  • ADC platform

Where Mersana Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Mersana Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Licensing and milestone payments: Mersana generated revenue through licensing agreements with pharmaceutical partners, receiving milestone payments upon achievement of clinical and regulatory milestones. GSK partnership provided $100 million option payment; milestone payments from GSK were mentioned in Q3 2025 results.

Mersana Therapeutics product offering

Product offering

Core offering

Mersana Therapeutics developed clinical-stage antibody-drug conjugates (ADCs) for the treatment of cancer. Its lead candidate, Emi-Le (emiltatug ledadotin), was a B7-H4-directed ADC in development for adenoid cystic carcinoma, a rare cancer with no approved therapies. The company also developed XMT-2056, a STING agonist ADC licensed to GSK. Revenue was generated through licensing and milestone payments from pharmaceutical partners.

Product overview

Mersana Therapeutics was a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment. The company's primary product was Emi-Le (emiltatug ledadotin), a B7-H4-directed ADC being developed for adenoid cystic carcinoma. Mersana also developed XMT-2056, a STING agonist ADC that was licensed to GSK. The company operated its proprietary ADC platform technology and was acquired by Day One Biopharmaceuticals in January 2026 for approximately $285 million.

Differentiator

Problem solved

Functional benefit

Brands

  • Emi-Le (emiltatug ledadotin): Antibody drug conjugate targeting B7-H4 for treating adenoid cystic carcinoma

Products and services

  • Emi-Le (emiltatug ledadotin) A clinical-stage antibody-drug conjugate (ADC) targeting B7-H4 for the treatment of adenoid cystic carcinoma (ACC), a rare cancer with no approved therapies. Developed by Mersana Therapeutics and now advanced by Day One Biopharmaceuticals following its January 2026 acquisition of Mersana.
  • XMT-2056 A STING agonist antibody-drug conjugate (ADC) for HER2-positive cancers, originally licensed to GSK. Development was discontinued in April 2026 after GSK terminated the partnership following an FDA partial clinical hold related to serious bleeding events.

Quantifiable outcome

  • 60.57% share tender acceptance in acquisition

Companies that use Mersana Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

Mersana Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Mersana Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered major (terminated) and core (acquisition completed).

  • GSKmajor (terminated)Strategic or Co-development Partner · 29 April 2026GSK partnered with Mersana on XMT-2056, a STING-agonist ADC for HER-2 cancers. GSK terminated the partnership in April 2026, walking away from a $100 million option deal. The drug had been placed on FDA partial clinical hold due to serious bleeding events including five deaths. GSK had originally acquired the program in 2022 in a deal worth up to $1.36 billion in milestones.
  • Day One Biopharmaceuticalscore (acquisition completed)Strategic or Co-development Partner · 6 January 2026Day One Biopharmaceuticals acquired Mersana Therapeutics in January 2026 for $25 per share in cash plus contingent value rights worth up to $30.25 per share. The acquisition added Emi-Le (B7-H4-directed ADC) to Day One's pipeline for treating adenoid cystic carcinoma. Mersana became a wholly owned subsidiary with immediate delisting from Nasdaq.

Scale indicators4 records

Recent moves7 records

Expansion highlights3 records

Mersana Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • ImmunoGen (AbbVie): ADC pioneer whose Elaherte (mirvetuximab) was acquired by AbbVie for $10.1B in 2024. Directly comparable to Mersana as a clinical-to-commercial ADC specialist targeting oncology indications.
  • Seagen (Pfizer): Leading ADC company with approved products (Adcetris, Padcev, Tukysa) acquired by Pfizer for $43B. Directly comparable ADC platform company with both early-stage assets and commercialized products.
  • Daiichi Sankyo: Co-developer of Enhertu (with AstraZeneca), a blockbuster HER2 ADC. Comparable as a major ADC innovator and commercializer with deep pipeline in antibody-drug conjugates across multiple targets.
  • Day One Biopharmaceuticals: Acquirer of Mersana and operator of Emi-Le post-2026; commercial-stage rare oncology company with FDA-approved OJEMDA. Comparable as a rare pediatric oncology-focused biopharma now integrating Mersana's ADC asset.
  • AstraZeneca: Major ADC player through Enhertu (with Daiichi Sankyo) and Datroway. Comparable as a large pharma with significant ADC franchise investments, demonstrating the strategic value of ADC assets Mersana-style companies can attract.
  • Gilead Sciences: Owns Trodelvy, a TROP2-directed ADC acquired through the Immunomedics deal. Comparable as a major biopharma with commercialized ADC assets and ongoing investments in antibody-drug conjugate development.

Direct peers

  • Bolt Biotherapeutics: Clinical-stage ADC/ISAC developer with proprietary platform technology. Comparable as a small-cap, clinical-stage ADC company developing next-generation antibody conjugates for oncology indications.
  • ProfoundBio: Clinical-stage ADC company developing novel antibody-drug conjugates for solid tumors. Directly comparable as a clinical-stage ADC specialist targeting oncology with proprietary platform technology.
  • Pyxis Oncology: Clinical-stage oncology company developing ADC and immuno-oncology therapeutics. Comparable as a clinical-stage biopharma focused on ADC development for cancer treatment.

Emerging players

  • Mablink Bioscience: Emerging ADC developer focused on next-generation antibody-drug conjugates with novel payload and linker technologies. Comparable as an emerging European-headquartered ADC platform company in clinical-stage development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Mersana Therapeutics social profiles

Digital presence

Mersana Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mersana Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Mersana Therapeutics funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mersana Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mersana Therapeutics

What does Mersana Therapeutics do?

Mersana Therapeutics developed clinical-stage antibody-drug conjugates (ADCs) for the treatment of cancer. Its lead candidate, Emi-Le (emiltatug ledadotin), was a B7-H4-directed ADC in development for adenoid cystic carcinoma, a rare cancer with no approved therapies. The company also developed XMT-2056, a STING agonist ADC licensed to GSK. Revenue was generated through licensing and milestone payments from pharmaceutical partners.

Is Mersana Therapeutics a public or private company?

Mersana Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Mersana Therapeutics founded?

Mersana Therapeutics was founded in 2017. It employs 51 to 100 people.

Where is Mersana Therapeutics based?

Mersana Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Mersana Therapeutics make money?

One revenue line is on record: licensing and milestone payments.

Who are Mersana Therapeutics's main competitors?

Broad incumbents on record are ImmunoGen (AbbVie), Seagen (Pfizer), Daiichi Sankyo, Day One Biopharmaceuticals, AstraZeneca and Gilead Sciences. Direct peers are Bolt Biotherapeutics, ProfoundBio and Pyxis Oncology. Mablink Bioscience is listed as an emerging player.

Does Mersana Therapeutics have an API?

No public API is recorded for Mersana Therapeutics.

What industry is Mersana Therapeutics in?

Mersana Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestDawn says total could rise to $250 billion by end of the yearDay One Biopharmaceuticals announced a definitive agreement for Servier to acquire it for a total equity value of $2.5 billion, following the company's completion of its acquisition of Mersana Therapeutics in January 2026. Day One reported preliminary 2025 net product revenue of $155.4 million, a 172% year-over-year increase driven by its flagship product OJEMDA, and reaffirmed its 2026 U.S. revenue guidance between $225 million and $250 million. The transaction is expected to provide additional resources to accelerate pipeline development and expand into new therapeutic areas.BioSpaceCytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal OfficerCytomX Therapeutics appointed Alejandra Carvajal as Chief Legal Officer, effective immediately. She brings over two decades of legal experience, most recently as Chief Legal Officer at Mersana Therapeutics. The appointment aims to support the company's clinical pipeline and long-term growth.GlobeNewswireCytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal OfficerCytomX Therapeutics appointed Alejandra Carvajal as Chief Legal Officer, effective immediately. She previously served as Chief Legal Officer at Mersana Therapeutics and Momenta Pharmaceuticals. The appointment aims to support the company's clinical pipeline and growth.Stock TitanActuate adds ex-Mersana CEO Martin Huber to boardActuate Therapeutics, Inc. announced the appointment of Martin Huber, MD as an Independent Director to its Board of Directors, effective immediately, strengthening the company's leadership as it advances its lead drug candidate elraglusib across multiple difficult-to-treat cancer indications toward registration studies. Huber brings over two decades of oncology drug development experience, having most recently served as President and CEO of Mersana Therapeutics until its acquisition by Day One Pharmaceuticals in January 2026. The appointment is expected to support Actuate's mission to develop novel cancer therapies targeting the GSK-3β pathway, with elraglusib showing promising results in metastatic pancreatic cancer.BioSpaceGSK’s Shingrix strategy shift drives sales beat even as vaccines slowGSK reported Q1 sales of £7.6 billion ($10.27 billion), a 5% year-on-year increase, driven by strong Shingrix performance despite an overall 9% decline in vaccine sales. Shingrix sales jumped 20% to nearly $1.4 billion after GSK shifted its commercialization strategy to focus on patients with comorbid conditions like diabetes or heart problems, with growth of 51% in Europe and 12% in the U.S. GSK also disclosed it has discontinued development of STING agonist XMT-2056, an antibody-drug conjugate acquired from Mersana Therapeutics in a 2022 deal worth up to $1.36 billion in milestones.FierceBiotechGSK walks away from $100M bet on Mersana's STING ADC, pauses mRNA bird flu shot programGSK has terminated its partnership with Mersana Therapeutics, walking away from a $100 million option deal for XMT-2056, a STING-agonist ADC for HER-2 cancers that had been placed on FDA partial clinical hold due to serious bleeding events including five deaths. The British pharma also disclosed it has paused its mRNA bird flu vaccine program to prioritize its seasonal flu mRNA vaccine currently in Phase 2, and discontinued a TLR8 agonist for chronic hepatitis B. The moves come as GSK ramps up its broader ADC strategy, planning five late-stage trials of a B7-H4-directed ADC licensed from Hansoh Pharma.GlobeNewswireDay One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue GuidanceDay One Biopharmaceuticals reported Q4 and full-year 2025 net product revenues of $52.8 million and $155.4 million, respectively, and reaffirmed its 2026 U.S. OJEMDA revenue guidance of $225–$250 million. The company also announced the January 2026 acquisition of Mersana Therapeutics and ongoing pipeline progress.openPR.comUS & EU Melanoma Therapeutics Market (2033): Growth Drivers, Investment OpportunitiesThe US & EU Melanoma Therapeutics market reached US$ 3.89 billion in 2024 and is projected to grow to US$ 8.99 billion by 2033, driven by rising melanoma incidence, advances in immunotherapy and targeted therapies, and supportive regulatory frameworks. Recent clinical developments include FDA Orphan Drug Designation for TuHURA Biosciences' IFx-2.0, positive Phase 2 data from IDEAYA Biosciences' darovasertib, and Day One Biopharmaceuticals' acquisition of Mersana Therapeutics for US$ 129 million (potentially US$ 285 million with milestones). Investment from major pharmaceutical companies including Merck, Bristol-Myers Squibb, and Novartis continues to fuel pipeline development against melanoma resistance and rare subtypes.Investing.comDay one Biopharma CCO sold $67k in DAWN stock By Investing.comLauren Merendino, Chief Commercial Officer of Day One Biopharmaceuticals, sold 5,814 shares of common stock on February 17, 2026, for approximately $67,447, while also exercising 15,162 RSUs on February 15, 2026. The company reported preliminary 2025 net product revenue of $155.4 million for its OJEMDA drug, representing 172% year-over-year growth, with 2026 guidance projecting $225–250 million in U.S. net product revenue. Day One has also completed its acquisition of Mersana Therapeutics for $25 per share plus contingent value rights worth up to $30.25 per share, and received positive analyst coverage following strong FIREFLY-1 trial data showing 77% of patients remained treatment-free for at least 12 months.